Dietary supplement adverse event reporting rules effective Dec. 22

The approval for tovorafenib (Ojemda) was based on data from the phase 2 FIREFLY-1 trial, in which the therapy demonstrated an overall repose rate of 67%.

Don Arthur, RPh, discusses what lays ahead in independent pharmacy, from clinical care to success stories.

Check out important updates from the FDA for the week of April 15.

Learn more about the ins and outs of pharmacy ownership from the experts at First Financial Bank.

The company’s investigational ABCWY vaccine candidate will be reviewed by the FDA by February 14, 2025.

Test your pharmacy news knowledge with our weekly quiz.